Cue Biopharma Inc (CUE)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$18.66-1.22%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cue Biopharma Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1M
EPS	—	-1.757
Annual ending 2026-12-31
Revenue	—	15.62M
EPS	—	-25.01
Annual ending 2027-12-31
Revenue	—	8.65M
EPS	—	-7.443

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve clinical milestones for CUE-221 and CUE-401	Cue Biopharma is working on important clinical goals for CUE-221 and CUE-401.	Improving	Failure to advance clinical milestones for CUE-221 and CUE-401 by FY26	CUE-221 Phase 2 primary endpoint met vs FY26 target Positive Phase 2 topline results for CUE-221 in CSU announced Sept 2026; CUE-401 data absent. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful execution of license agreement with Ascendant Health Sciences	It has a license deal with Ascendant Health Sciences.	Intact	License agreement with Ascendant Health Sciences fails or stalls by FY26	Qualitative: Phase 2 met primary endpoint Positive Phase 2 topline results for CUE-221 in CSU announced Sept 20, 2026, conducted by Genesis Life Sciences (Ascendant affiliate). Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 disclosures including 2026-Q1 and 2026-Q2 press releases and material event filing. The license agreement contributed to revenue growth from $0.4M in 2025-Q1 to $7.9M in 2026-Q2 due to milestone achievements. Management consistently emphasizes the license as a key growth driver, showing delivery through portfolio expansion and revenue recognition. Delivery assessment Oct 24, 2026
Stability in management and board leadership	A primary condition in Cue Biopharma Inc's published investment case. The stated target is No further major board resignations or CEO changes through 2026.	Under Pressure	Additional major board resignations or CEO departures in 2026	4 board resignations in Jun 2026 vs 0 target News confirms four directors resigned from the board in June 2026, directly violating the stability target. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Progress in strategic partnership with Boehringer Ingelheim	The company also has a partnership with Boehringer Ingelheim.	Intact	No progress in compound selection or lead optimization by FY26	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable	1 / 1
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 1
2026-08-01	Unavailable	Unavailable	1 / 1
2026-08-02	Unavailable	Unavailable	1 / 1
2026-08-03	Unavailable	Unavailable	1 / 1
2026-08-04	Unavailable	Unavailable	1 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	1 / 1
2026-08-07	Unavailable	Unavailable	1 / 1
2026-08-08	Unavailable	Unavailable	1 / 1
2026-08-09	Unavailable	Unavailable	1 / 1
2026-08-10	Unavailable	Unavailable	1 / 1
2026-08-11	Unavailable	Unavailable	1 / 1
2026-08-12	Unavailable	Unavailable	1 / 1
2026-08-13	Unavailable	Unavailable	1 / 1
2026-08-14	Unavailable	Unavailable	1 / 1
2026-08-15	Unavailable	Unavailable	1 / 1
2026-08-16	Unavailable	Unavailable	1 / 1
2026-08-17	Unavailable	Unavailable	1 / 1
2026-08-18	Unavailable	Unavailable	1 / 1
2026-08-19	Unavailable	Unavailable	1 / 1
2026-08-20	Unavailable	Unavailable	1 / 1
2026-08-21	Unavailable	Unavailable	1 / 1
2026-08-22	Unavailable	Unavailable	1 / 1
2026-08-23	Unavailable	Unavailable	1 / 1
2026-08-24	Unavailable	Unavailable	1 / 1
2026-08-25	Unavailable	Unavailable	1 / 1
2026-08-26	Unavailable	Unavailable	1 / 1
2026-08-27	Unavailable	Unavailable	1 / 1
2026-08-28	Unavailable	Unavailable	1 / 1
2026-08-29	Unavailable	Unavailable	1 / 1
2026-08-30	Unavailable	Unavailable	1 / 1
2026-08-31	Unavailable	Unavailable	2 / 1
2026-09-01	Unavailable	Unavailable	2 / 1
2026-09-02	Unavailable	Unavailable	2 / 1
2026-09-03	Unavailable	Unavailable	2 / 2
2026-09-04	Unavailable	Unavailable	2 / 2
2026-09-05	Unavailable	Unavailable	2 / 2
2026-09-06	Unavailable	Unavailable	2 / 2
2026-09-07	Unavailable	Unavailable	2 / 2
2026-09-08	Unavailable	Unavailable	2 / 2
2026-09-09	Unavailable	Unavailable	2 / 2
2026-09-10	Unavailable	Unavailable	2 / 2
2026-09-11	Unavailable	Unavailable	2 / 2
2026-09-12	Unavailable	Unavailable	2 / 2
2026-09-13	Unavailable	Unavailable	2 / 2
2026-09-14	Unavailable	Unavailable	2 / 2
2026-09-15	Unavailable	Unavailable	2 / 2
2026-09-16	Unavailable	Unavailable	2 / 2
2026-09-17	Unavailable	Unavailable	2 / 2
2026-09-18	Unavailable	Unavailable	2 / 2
2026-09-19	Unavailable	Unavailable	2 / 2
2026-09-20	Unavailable	Unavailable	2 / 2
2026-09-21	Unavailable	Unavailable	3 / 3
2026-09-22	Unavailable	Unavailable	3 / 3
2026-09-23	Unavailable	Unavailable	2 / 2
2026-09-24	Unavailable	Unavailable	2 / 2
2026-09-25	Unavailable	Unavailable	2 / 2
2026-09-26	Unavailable	Unavailable	2 / 2
2026-09-27	Unavailable	Unavailable	2 / 2
2026-09-28	Unavailable	Unavailable	2 / 2
2026-09-29	Unavailable	Unavailable	2 / 2
2026-09-30	Unavailable	Unavailable	2 / 2
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	0	0
2026-06-01	1	0	0
2026-07-01	1	0	0
2026-08-01	2	0	0
2026-09-01	3	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

B.Riley FinancialOct 1

$83.00New observation · no comparable prior

$0$45.65$91.30

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Stability in management and board leadershipPublished status: Under Pressure
Progress in strategic partnership with Boehringer IngelheimQualitative condition

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

4.5%Typical daily move · historical

Downside history

-77.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cue Biopharma Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not a proven compounder: the business is loss-making and recent performance is weak. The thesis is on watch, with management delivering some clinical and licensing milestones but facing volatile execution and high risk.

What's priced into Cue Biopharma Inc

The valuation evidence is mixed: one measure points to CUE being cheap versus peers, while another shows a 34% premium, and model confidence is low. Expectations appear close to the evidence, with a small negative gap; the snapshot reports no major fragility signals.

What the fundamentals likely do

Near term, revenue has risen with collaboration milestones, and management remains on track for the CUE-221 data readout and CUE-401 trial initiation. The company has raised funds through private placements, but cash declined after spending, while weak performance, a litigation filing, and a CFO transition add uncertainty.

What Cue Biopharma Inc hinges on

Over the next few quarters, the thesis depends on clinical milestones arriving on schedule and collaboration activity continuing to support revenue. A guidance cut or further weakening in jobs data would add pressure; continued strength from healthcare bellwethers could support the sector backdrop.